Abstract

Nephrotic syndrome is an important presentation of glomerular disease characterised by heavy proteinuria, hypoalbuminaemia and oedema. The differential diagnosis of the underlying condition is wide including primary renal disorders and secondary diseases such as malignancy, infection, diabetes and amyloid. Presentations to acute medicine may be with hypervolaemia, complications of the nephrotic state (such as venous thromboembolism), or complications of therapy (such as infection).

Early recognition of nephrotic syndrome is possible through simple urinalysis for protein and testing serum albumin, although a high index of suspicion is sometimes required in patients with comorbidities including potentially distracting cardiac or hepatic diseases.

[download-attachments container="div" style="list" display_icon="1" display_count="1" display__size="0"]

References

1. Tryggvason K, Patrakka J, Wartiovaara J. Hereditary proteinuria syndromes and mechanisms of proteinuria. N Engl J Med. 2006 Mar 30;354(13):1387-401
2. Siddall EC, Radhakrishnan J. The pathophysiology of edema formation in the nephrotic syndrome. Kidney Int. 2012 Sep;82(6):635-42
3. Chapter 2: General principles in the management of glomerular disease. Kidney Int Suppl (2011). 2012 Jun;2(2):156-62
4. Radhakrishnan J, Appel AS, Valeri A et al. The nephrotic syndrome, lipids, and risk factors for cardiovascular disease. Am J Kidney Dis. 1993 Jul;22(1):135-42
5. Clement LC, Mace C, Avila-Casado C et al. Circulating angiopoietin-like 4 links proteinuria with hypertriglyceridemia in nephrotic syndrome. Nat Med. 2014 Jan;20(1):37-46
6. Ordoñez JD, Hiatt RA, Killebrew EJ et al. The increased risk of coronary heart disease associated with nephrotic syndrome. Kidney International. 1993;44(3):638-42
7. Loscalzo J. Venous thrombosis in the nephrotic syndrome. N Engl J Med. 2013 Mar 7;368(10):956-8
8. Zwaginga JJ, Koomans HA, Sixma JJ et al. Thrombus formation and plateletvessel wall interaction in the nephrotic syndrome under flow conditions. J Clin Invest. 1994 Jan;93(1):204-11
9. Kauffmann RH, Veltkamp JJ, Van Tilburg NH et al. Acquired antithrombin III deficiency and thrombosis in the nephrotic syndrome. Am J Med. 1978 Oct;65(4):607-13
10. Kerlin BA, Ayoob R, Smoyer WE. Epidemiology and pathophysiology of nephrotic syndrome-associated thromboembolic disease. Clin J Am Soc Nephrol. 2012 Mar;7(3):513-20
11. Alkjaersig N, Fletcher AP, Narayanan M et al. Course and resolution of the coagulopathy in nephrotic children. Kidney Int. 1987 Mar;31(3):772-80
12. Orth SR, Ritz E. The nephrotic syndrome. N Engl J Med. 1998 Apr 23;338(17):1202-11
13. Haas M, Meehan SM, Karrison TG et al. Changing etiologies of unexplained adult nephrotic syndrome: a comparison of renal biopsy findings from 1976-1979 and 1995-1997. Am J Kidney Dis. 1997 Nov;30(5):621-31
14. Shalhoub RJ. Pathogenesis of lipoid nephrosis: a disorder of T-cell function. Lancet. 1974 Sep 7;2(7880):556-60
15. Saleem MA, Kobayashi Y. Cell biology and genetics of minimal change disease. F1000Res. 2016;5
16. Abdel-Hafez M, Shimada M, Lee PY et al. Idiopathic nephrotic syndrome and atopy: is there a common link? Am J Kidney Dis. 2009 Nov;54(5):945-53
17. Vivarelli M, Massella L, Ruggiero B et al. Minimal Change Disease. Clin J Am Soc Nephrol. 2017 Feb 7;12(2):332-45
18. Chapter 5: Minimal-change disease in adults. Kidney Int Suppl (2011). 2012 Jun;2(2):177-80
19. Sinha A, Bajpai J, Saini S et al. Serum-soluble urokinase receptor levels do not distinguish focal segmental glomerulosclerosis from other causes of nephrotic
    syndrome in children. Kidney Int. 2014 Mar;85(3):649-58
20. Wada T, Nangaku M. A circulating permeability factor in focal segmental glomerulosclerosis: the hunt continues. Clin Kidney J. 2015 Dec;8(6):708-15
21. Rosenberg AZ, Kopp JB. Focal Segmental Glomerulosclerosis. Clin J Am Soc Nephrol. 2017 Mar 7;12(3):502-17
22. D’Agati VD, Kaskel FJ, Falk RJ. Focal segmental glomerulosclerosis. N Engl J Med. 2011 Dec 22;365(25):2398-411
23. Kopp JB, Nelson GW, Sampath K et al. APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol. 2011 Nov;22(11):2129-37
24. Troyanov S, Wall CA, Miller JA et al. Focal and segmental glomerulosclerosis: definition and relevance of a partial remission. J Am Soc Nephrol. 2005 Apr;16(4):1061-8
25. Chapter 6: Idiopathic focal segmental glomerulosclerosis in adults. Kidney Int Suppl (2011). 2012 Jun;2(2):181-5
26. Hanko JB, Mullan RN, O’Rourke DM et al. The changing pattern of adult primary glomerular disease. Nephrol Dial Transplant. 2009 Oct;24(10):3050-4
27. McQuarrie EP, Mackinnon B, Stewart GA et al. Membranous nephropathy remains the commonest primary cause of nephrotic syndrome in a northern
    European Caucasian population. Nephrol Dial Transplant. 2010 Mar;25(3):1009- 10; author reply 10-1
28. De Vriese AS, Glassock RJ, Nath KA et al. A Proposal for a SerologyBased Approach to Membranous Nephropathy. J Am Soc Nephrol. 2017 Feb;28(2):421-30
29. Couser WG. Primary Membranous Nephropathy. Clin J Am Soc Nephrol. 2017 Jun 7;12(6):983-97
30. Beck LH, Jr., Bonegio RG, Lambeau G et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009 Jul 2;361(1):11-21
31. Hofstra JM, Debiec H, Short CD et al. Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy. J Am Soc Nephrol. 2012 Oct;23(10):1735-43
32. Jha V, Ganguli A, Saha TK et al. A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy. J Am Soc Nephrol. 2007 Jun;18(6):1899-904
33. Chapter 7: Idiopathic membranous nephropathy. Kidney Int Suppl (2011). 2012 Jun;2(2):186-97
34. Bomback AS, Appel GB. Pathogenesis of the C3 glomerulopathies and reclassification of MPGN. Nat Rev Nephrol. 2012 Nov;8(11):634-42
35. De Vita S, Quartuccio L, Isola M et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum. 2012 Mar;64(3):843-53
36. Jha V, Garcia-Garcia G, Iseki K et al. Chronic kidney disease: global dimension and perspectives. The Lancet. 2013;382(9888):260-72
37. Guardia JA, Ortiz-Butcher C, Bourgoignie JJ. Oncotic pressure and edema formation in hypoalbuminemic HIV-infected patients with proteinuria. Am J Kidney Dis. 1997 Dec;30(6):822-8
38. Booth JW, Hamzah L, Jose S et al. Clinical characteristics and outcomes of HIV-associated immune complex kidney disease. Nephrol Dial Transplant. 2016 Dec;31(12):2099-107
39. Rosenberg AZ, Naicker S, Winkler CA et al. HIV-associated nephropathies: epidemiology, pathology, mechanisms and treatment. Nat Rev Nephrol. 2015 Mar;11(3):150-60
40. Post FA, Campbell LJ, Hamzah L et al. Predictors of renal outcome in HIVassociated nephropathy. Clin Infect Dis. 2008 Apr 15;46(8):1282-9
41. Hanly JG, O’Keeffe AG, Su L et al. The frequency and outcome of lupus nephritis: results from an international inception cohort study. Rheumatology (Oxford). 2016 Feb;55(2):252-62
42. Weening JJ, D’Agati VD, Schwartz MM et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int. 2004 Feb;65(2):521-30
43. Sloan RP, Schwartz MM, Korbet SM et al. Long-term outcome in systemic lupus erythematosus membranous glomerulonephritis. Lupus Nephritis Collaborative Study Group. J Am Soc Nephrol. 1996 Feb;7(2):299-305
44. Wilhelmus S, Bajema IM, Bertsias GK et al. Lupus nephritis management guidelines compared. Nephrol Dial Transplant. 2016 Jun;31(6):904-13
45. Kraft SW, Schwartz MM, Korbet SM et al. Glomerular podocytopathy in patients with systemic lupus erythematosus. J Am Soc Nephrol. 2005 Jan;16(1):175-9
46. Hu W, Chen Y, Wang S et al. Clinical-Morphological Features and Outcomes of Lupus Podocytopathy. Clin J Am Soc Nephrol. 2016 Apr 7;11(4):585-92
47. Bridoux F, Leung N, Hutchison CA et al. Diagnosis of monoclonal gammopathy of renal significance. Kidney Int. 2015 Apr;87(4):698-711
48. Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. Lancet. 2016 Jun 25;387(10038):2641-54
49. Hogan JJ, Mocanu M, Berns JS. The Native Kidney Biopsy: Update and Evidence for Best Practice. Clin J Am Soc Nephrol. 2016 Feb 5;11(2):354-62
50. Kirchner KA, Voelker JR, Brater DC. Binding inhibitors restore furosemide potency in tubule fluid containing albumin. Kidney Int. 1991 Sep;40(3):418-24
51. Chronic Kidney Disease (Partial Update): Early Identification and Management of Chronic Kidney Disease in Adults in Primary and Secondary Care. National
    Institute for Health and Care Excellence: Clinical Guidelines. London2014.
52. Bramham K, Lightstone L. Pre-pregnancy counseling for women with chronic kidney disease. J Nephrol. 2012 Jul-Aug;25(4):450-9
53. Hebert LA, Wilmer WA, Falkenhain ME et al. Renoprotection: one or many therapies? Kidney Int. 2001 Apr;59(4):1211-26
54. Mathieson PW. Membranous nephropathy. Clin Med (Lond). 2012 Oct;12(5):461-6